Compare McKesson Corporation (MCK) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Vanguard S&P 500 ETF — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Vanguard S&P 500 ETF trades at $714.68 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 16.6× McKesson Corporation's market cap, and McKesson Corporation pays a 0.4% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Vanguard S&P 500 ETF for 55 Days on average.
| MCK | VOO | |
|---|---|---|
Market Cap | $108.46B | $1.80T |
Volume | 712,607 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $995.69 | $716.17 |
52-Week Low | $725.17 | $580.93 |
Typical Hold Time | 74 Days | 55 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
VOO trades at $714.42, down 0.24% with a mild bearish daily move. Technical indicators show a bullish moving average signal but neutral oscillators, with RSI at 75.83 suggesting potential overbought conditions. Recent news highlights the ETF's role in long-term wealth building amid expectations of slowing S&P 500 profit growth from 35% to 15% in 2027. Short interest increased 46.9% in September, indicating growing bearish bets.
The outlook remains cautiously optimistic given VOO's diversified exposure to the S&P 500, though elevated RSI and rising short interest signal near-term pressure. Key risks include macroeconomic headwinds from Fed rate hikes and projected earnings slowdown. The ETF continues to be favored for recession resilience and long-term dollar-cost averaging strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
